CDDO-Im (RTA-403)

Catalog No.S9723 Batch:S972301

Print

Technical Data

Formula
C34H43N3O3
Molecular Weight 541.72 CAS No. 443104-02-7
Solubility (25°C)* In vitro DMSO 56 mg/mL (103.37 mM)
Water Insoluble
Ethanol Insoluble
In Vivo (Add solvents to the product individually and in order.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description An activator of nuclear factor erythroid 2–related factor 2 (Nrf2) and peroxisome proliferator-activated receptor (PPAR), CDDO-Im (RTA-403) binds to PPAR and PPAR with Ki of 232 nM and 344 nM, respectively. It inhibits inflammatory response and tumour growth in vivo.
Targets
Nrf2 PPARα
(Cell-free assay)		 PPARγ
(Cell-free assay)
232 nM(Ki) 344 nM(Ki)
In vitro

CDDO-Im (RTA-403) is highly active in suppressing cellular proliferation of human leukaemia and breast cancer cell lines (IC50, 10–30 nM). In U937 leukaemia cells, it also induces monocytic differentiation as measured by increased cell surface expression of CD11b and CD36. This compound has significant actions independent of PPAR transactivation.
In Vivo

CDDO-Im (RTA-403) is a novel synthetic triterpenoid more potent than its parent compound (CDDO). In vivo, it is a potent inhibitor of de novo inducible nitric oxide synthase expression in primary mouse macrophages. Moreover, this compound inhibits growth of B16 murine melanoma and L1210 murine leukaemia cells in vivo.

Protocol (from reference)

Cell Assay:

[2]
  • Cell Lines

    U937, THP-1, and HL-60 leukemia cells

  • Concentrations

    100 pM to 1 μM

  • Incubation Time

    5 days

  • Method

    U937, THP-1, and HL-60 leukemia cells are treated with either control vehicle, CDDO, or CDDO-Im (RTA-403) at concentrations ranging from 100 pM to 1 μM, and after 5 days, proliferation is measured by cell counting.
Animal Study:

[2]
  • Animal Models

    female CD-1 mice, male and female BDF-1 mice

  • Dosages

    1 nmole, 10 nmole

  • Administration

    IP

References

  • https://pubmed.ncbi.nlm.nih.gov/15930299/
  • https://pubmed.ncbi.nlm.nih.gov/12855660/

Sellecks CDDO-Im (RTA-403) Has Been Cited by 2 Publications

Melatonin attenuates polystyrene microplastics induced motor neurodevelopmental defect in zebrafish (Danio rerio) by activating nrf2 - isl2a Axis [ Ecotoxicol Environ Saf, 2022, 241:113754] PubMed: 35709674
Genetic Ablation of Nrf2 Exacerbates Neuroinflammation in Ocular Autoimmunity [ Int J Mol Sci, 2022, 23(19)11715] PubMed: 36233013

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.